布鲁氏菌病疫苗市场- 类型（RB51、S19、B19 疫苗）、疫苗（DNA、亚单位、载体疫苗）、动物类型（牛、绵羊、山羊）、最终用户（兽医诊所和医院、动物护理中心）、全球预测（2024 - 2032）

由于全球家畜和动物疫苗接种工作不断增加，2024 年至 2032 年间，全球布鲁氏菌病疫苗市场复合年增长率将达到 4.9%。布鲁氏菌病是一种影响多种动物的传染病，对农业和公共卫生构成重大风险。在非洲、亚洲和拉丁美洲部分地区等牲畜数量较多的地区，政府和农业组织正在加强疫苗接种计划，以控制和根除布鲁氏菌病。这些措施是出于保护动物健康、加强粮食安全和防止人畜共患病传播给人类的需要而推动的。例如，2023 年 9 月，昌迪加尔政府根据联邦政府国家动物疾病控制计划，为 21,000 多头牲畜接种了口蹄疫 (FMD) 疫苗。这项倡议包括牛、水牛、山羊、绵羊和猪，免费提供口蹄疫和布鲁氏菌病疫苗接种。

在已开发地区，严格的动物健康法规和生物安全措施支持了正在进行的疫苗接种工作。随着人们对布鲁氏菌病影响的认识不断增强，公共和私营部门都在投资先进的疫苗开发和分发。全球对全面疫苗接种策略的推动正在推动市场成长，确保更好地控制布鲁氏菌病，并支持永续的牲畜管理实践。

整个布鲁氏菌病疫苗产业根据类型、疫苗、动物类型、最终用户和地区进行分类。

根据类型，S19疫苗领域的布鲁氏菌病疫苗市场收入将在2024年至2032年实现令人称讚的复合年增长率。其他动物的布鲁氏菌病疫情。它能够诱导强烈的免疫反应并降低疾病盛行率，这对于预防感染和保障动物健康至关重要。随着农业产业和政府优先考虑疾病控制和公共卫生，S19 疫苗的采用正在推动市场需求的增加。这一激增反映了全球对改善牲畜管理和减轻布鲁氏菌病影响的承诺。

在疫苗方面，次单位疫苗部分将在2024年至2032年显着增加。它们的精确性和不良反应风险的降低使它们对牲畜疫苗接种计划极具吸引力。随着农业实践的进步和有效疾病管理需求的增长，亚单位疫苗正在成为控制布鲁氏菌病爆发的首选。它们的开发和采用促进了市场需求的显着增长，反映出向更安全、更有效率的疫苗接种解决方案的转变。

2024年至2032年，欧洲布鲁氏菌病疫苗市场将呈现显着的复合年增长率。 。随着农民和政府寻求有效的解决方案来管理和根除布鲁氏菌病，欧盟强有力的动物健康政策和疫苗接种计划资金推动了市场成长。由于该地区注重维持动物福利和食品安全的高标准，欧洲的布鲁氏菌病疫苗市场正经历显着的扩张和投资。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 布鲁氏菌病率增加
    • 增加畜牧业生产
    • 对人畜共通传染病的认识不断提高
  • 产业陷阱与挑战
    • 动物疫苗的严格监管要求
• 成长潜力分析
• 监管环境
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• RB51疫苗
• S19疫苗
• B19 疫苗
• 其他类型

第 6 章：市场估计与预测：按疫苗分类，2021 - 2032 年

• 主要趋势
• DNA疫苗
• 亚单位疫苗
• 载体疫苗
• 重组疫苗

第 7 章：市场估计与预测：按动物类型，2021 - 2032

• 主要趋势
• 牛
• 羊
• 山羊
• 其他动物类型

第 8 章：市场估计与预测：按最终用户划分，2021 - 2032 年

• 主要趋势
• 兽医诊所和医院
• 动物照护中心
• 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Ceva
• Colorado Serum Company
• Creative Biolabs
• CZ Vaccines
• Fivet Animal Health
• Hester Biosciences Limited
• Indian Immunologicals Ltd.
• Jordan Bio-industries Center
• Laboratories Tornel
• Merck & Co., Inc.
• VETAL Animal Health Products Inc.
• Veterinary Technologies Corporation

Global Brucellosis Vaccine Market will witness 4.9% CAGR between 2024 and 2032 due to rising vaccination efforts for livestock and animals globally. Brucellosis, a contagious disease affecting various animals, poses significant risks to agricultural industries and public health. In regions with high livestock populations, such as parts of Africa, Asia, and Latin America, governments and agricultural organizations are intensifying vaccination programs to control and eradicate Brucellosis. These initiatives are driven by the need to protect animal health, enhance food security, and prevent zoonotic transmission to humans. For instance, in September 2023, the Chandigarh administration vaccinated more than 21,000 livestock against foot and mouth disease (FMD) under the National Animal Disease Control Programme of the Union government. This initiative, which included cattle, buffalo, goats, sheep, and pigs, provided free vaccinations against both FMD and Brucellosis.

In developed regions, ongoing vaccination efforts are bolstered by stringent animal health regulations and biosecurity measures. As awareness of Brucellosis's impact grows, both public and private sectors are investing in advanced vaccine development and distribution. This global push towards comprehensive vaccination strategies is fueling market growth, ensuring better control of Brucellosis, and supporting sustainable livestock management practices.

The overall Brucellosis Vaccine Industry is classified based on the type, vaccine, animal type, end-user, and region.

Based on type, the brucellosis vaccine market revenue from the S19 vaccines segment will register a commendable CAGR from 2024 to 2032. The S19 vaccine, known for its efficacy and long-lasting protection, is widely used to control brucellosis outbreaks among cattle and other animals. Its ability to induce strong immune responses and reduce disease prevalence makes it crucial for both preventing infections and safeguarding animal health. As agricultural industries and governments prioritize disease control and public health, the adoption of S19 vaccines is driving increased market demand. This surge reflects the global commitment to improving livestock management and mitigating brucellosis impacts.

In terms of vaccine, the sub-unit vaccines segment will witness an appreciable growth from 2024 to 2032. Subunit vaccines, which contain only specific antigens from the Brucella bacterium, provide targeted protection without the risk of causing disease. Their precision and reduced risk of adverse reactions make them highly attractive for livestock vaccination programs. As agricultural practices advance and the need for effective disease management grows, subunit vaccines are becoming a preferred choice for controlling brucellosis outbreaks. Their development and adoption are contributing to a significant rise in market demand, reflecting a shift towards safer and more efficient vaccination solutions.

Europe brucellosis vaccine market will exhibit a notable CAGR from 2024 to 2032. European countries are prioritizing vaccination to prevent brucellosis outbreaks, which can impact both animal health and public safety. The European Union's robust animal health policies and funding for vaccination programs drive market growth as farmers and governments seek effective solutions to manage and eradicate brucellosis. As the region focuses on maintaining high standards of animal welfare and food security, the brucellosis vaccine market in Europe is experiencing significant expansion and investment.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of brucellosis
    • 3.2.1.2 Increasing livestock production
    • 3.2.1.3 Rising awareness about zoonotic diseases
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory requirements for animal vaccines
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 RB51 vaccines
• 5.3 S19 vaccines
• 5.4 B19 vaccines
• 5.5 Other types

Chapter 6 Market Estimates and Forecast, By Vaccine, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 DNA vaccines
• 6.3 Subunit vaccines
• 6.4 Vector vaccines
• 6.5 Recombinant vaccines

Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Cattle
• 7.3 Sheep
• 7.4 Goat
• 7.5 Other animal type

Chapter 8 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary clinics & hospitals
• 8.3 Animal care centers
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Ceva
• 10.2 Colorado Serum Company
• 10.3 Creative Biolabs
• 10.4 CZ Vaccines
• 10.5 Fivet Animal Health
• 10.6 Hester Biosciences Limited
• 10.7 Indian Immunologicals Ltd.
• 10.8 Jordan Bio-industries Center
• 10.9 Laboratories Tornel
• 10.10 Merck & Co., Inc.
• 10.11 VETAL Animal Health Products Inc.
• 10.12 Veterinary Technologies Corporation